Basilea Pharmaceutica (BSLN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the stock and has a CHF100.00 price target.
Ram Selvaraju has given his Buy rating due to a combination of factors including the upcoming U.S. launch of Basilea Pharmaceutica’s antibiotic, Zevtera, which is expected to generate significant revenue starting in 2026. Zevtera’s approval by the FDA for treating methicillin-resistant Staphylococcus aureus (MRSA) infections positions it uniquely in the market with limited competition. Additionally, the continued strong performance of Cresemba, an antifungal marketed by Pfizer, has resulted in substantial sales growth and milestone payments, further strengthening Basilea’s financial outlook.
Another contributing factor to the Buy rating is Basilea’s robust cash flow generation and the securing of non-dilutive funding commitments, which are expected to drive development without diluting shareholder value. The anticipated increase in royalty income and reimbursements from BARDA and CARB-X, coupled with strategic R&D investments, are projected to maintain operating profit levels. These elements collectively support a positive financial trajectory for Basilea, justifying the Buy recommendation.
In another report released on March 21, Kepler Capital also maintained a Buy rating on the stock with a CHF69.00 price target.